Open Access
ARTICLE
miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Xiao-Na L*i, Hong Yang†, Tao Yang‡
* The Department of General Surgery, Tongde Hospital of Zhejiang Province, Zhejiang Province, P.R. China
† The Department of Medical Oncology, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei Province, P.R. China
‡ The Department of Hepatological Surgery, Tongde Hospital of Zhejiang Province, Zhejiang Province, P.R. China
Oncology Research 2020, 28(1), 41-49. https://doi.org/10.3727/096504019X15615433287579
Abstract
In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the
mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level.
Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we
used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2),
and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay to test the
inhibition effect of miR-122 ASO therapy against hepatocarcinoma. miR-122 was reduced in hepatocarcinoma
tissues compared to the paracarcinoma tissues, which was relatively low or high in hepatocarcinoma cell line
SMMC7721 or Hep3B, and overexpressed miR-122 inhibited proliferation, migration, and invasion in hepatocarcinoma cells. Additionally, some reports showed that LMNB2 was regulated by miR-122, which inhibited
the expression of LMNB2. Moreover, LMNB2 functioned to promote cell proliferation, migration, and invasion. We could achieve the inhibition of hepatocarcinoma using miR-122 therapy through decreasing LMNB2
expression in vivo. Our data indicated that miR-122 could inhibit hepatocellular carcinoma cell progression by
targeting LMNB2 and as a therapeutic target for hepatocarcinoma treatment.
Keywords
Cite This Article
L, X., Yang, T. (2020). miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2.
Oncology Research, 28(1), 41–49.